<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114234</article-id><article-id pub-id-type="publisher-id">ACM-41657</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_96482648.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  调节性T细胞在肝脏移植免疫耐受中的作用
  Role of Regulatory T Cells in Immune Tolerance in Liver Transplantation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>剑</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>涛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>龚</surname><given-names>建平</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>重庆医科大学附属第二医院肝胆外科，重庆</addr-line></aff><aff id="aff2"><addr-line>重庆市璧山区妇幼保健院外科，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1630</fpage><lpage>1635</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    肝移植是终末肝病唯一有效的治疗方式，但是肝移植术后建立免疫耐受的问题一直没有得到很好的解决。人的肝脏含有不同的效应性淋巴细胞亚群，它们由调节性T细胞(regulatory t cells, Treg)的细胞亚群来控制。免疫抑制是抗原特异性的，这需要Treg的激活来协调完成。因此，Treg在维持肝移植免疫耐受方面具有至关重要的作用，是诱导肝移植免疫耐受形成的关键细胞。本文将就Treg与肝移植免疫耐受的关系以及相关机制进行简要介绍。
    Liver transplantation is the only effective treatment for terminal liver disease, but the problem of establishing immune tolerance after liver transplantation has not been well solved. The human liver contains different subsets of effector lymphocytes that are kept in check by a subpopulation as Regulatory T cells (Treg). Treg plays an important role in immune regulation, so the balance between effector and regulatory lymphocytes usually determines the outcome of liver immunity. Therefore, Treg plays a crucial role in maintaining immune tolerance in liver transplantation and is a key cell for inducing the formation of immune tolerance in liver transplantation. This article will briefly introduce the relationship between Treg and immune tolerance in liver transplantation as well as the relevant mechanisms. 
  
 
</p></abstract><kwd-group><kwd>调节性T细胞，肝移植，免疫耐受, Regulatory T Cells</kwd><kwd> Liver Transplantation</kwd><kwd> Immune Tolerance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>肝移植是终末肝病唯一有效的治疗方式，但是肝移植术后建立免疫耐受的问题一直没有得到很好的解决。人的肝脏含有不同的效应性淋巴细胞亚群，它们由调节性T细胞(regulatory t cells, Treg)的细胞亚群来控制。免疫抑制是抗原特异性的，这需要Treg的激活来协调完成。因此，Treg在维持肝移植免疫耐受方面具有至关重要的作用，是诱导肝移植免疫耐受形成的关键细胞。本文将就Treg与肝移植免疫耐受的关系以及相关机制进行简要介绍。</p></sec><sec id="s2"><title>关键词</title><p>调节性T细胞，肝移植，免疫耐受</p></sec><sec id="s3"><title>Role of Regulatory T Cells in Immune Tolerance in Liver Transplantation</title><p>Jian Zhang<sup>1</sup>, Tao Liu<sup>2</sup>, Jianping Gong<sup>2*</sup></p><p><sup>1</sup>Department of Surgery, Chongqing Bishan Area Maternal and Child Health Care, Chongqing</p><p><sup>2</sup>Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing</p><p><img src="//html.hanspub.org/file/27-1572143x4_hanspub.png" /></p><p>Received: Mar. 12<sup>th</sup>, 2021; accepted: Apr. 12<sup>th</sup>, 2021; published: Apr. 19<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/27-1572143x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Liver transplantation is the only effective treatment for terminal liver disease, but the problem of establishing immune tolerance after liver transplantation has not been well solved. The human liver contains different subsets of effector lymphocytes that are kept in check by a subpopulation as Regulatory T cells (Treg). Treg plays an important role in immune regulation, so the balance between effector and regulatory lymphocytes usually determines the outcome of liver immunity. Therefore, Treg plays a crucial role in maintaining immune tolerance in liver transplantation and is a key cell for inducing the formation of immune tolerance in liver transplantation. This article will briefly introduce the relationship between Treg and immune tolerance in liver transplantation as well as the relevant mechanisms.</p><p>Keywords:Regulatory T Cells, Liver Transplantation, Immune Tolerance</p><disp-formula id="hanspub.41657-formula24"><graphic xlink:href="//html.hanspub.org/file/27-1572143x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/27-1572143x8_hanspub.png" /> <img src="//html.hanspub.org/file/27-1572143x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>肝移植是治疗终末期肝病或不能切除的肝脏恶性肿瘤的最佳治疗方法 [<xref ref-type="bibr" rid="hanspub.41657-ref1">1</xref>]，但是术后免疫耐受建立的问题仍然没有得到很好的解决，受者停止所有免疫抑制药物并能够保持良好移植物功能的现象很少见，且已被证明发生在移植后的晚期，大多数患者需要维持终生免疫抑制以防止同种异体移植排斥反应 [<xref ref-type="bibr" rid="hanspub.41657-ref2">2</xref>]。移植后排斥反应是影响受体预后的主要非技术性因素。现有的经典免疫抑制方案很难做到长期免疫，或者伴有严重的副作用，在肝移植患者的死亡中，60%是由恶性肿瘤和心血管疾病等非肝病引起的，大约20%的患者经历了严重的肾功能障碍 [<xref ref-type="bibr" rid="hanspub.41657-ref2">2</xref>]。人们越来越关注更有效和更安全的策略来改善肝移植后的免疫排斥反应。</p><p>大量研究表明，调节性T细胞(regulatory t cells, Treg)在防止肝移植后排斥反应和诱导免疫耐受中起着核心作用 [<xref ref-type="bibr" rid="hanspub.41657-ref2">2</xref>]。免疫抑制是抗原特异性的，这需要Treg的激活来协调完成 [<xref ref-type="bibr" rid="hanspub.41657-ref3">3</xref>]，Treg是淋巴细胞，主要起免疫抑制作用，抑制过度的免疫反应，调节对自身抗原的耐受。</p><p>因此，Treg在诱导、维持肝脏移植物免疫耐受中发挥着关键作用。本文将就Treg与肝移植免疫耐受的关系以及相关机制进行讨论，以期为利用Treg诱导肝移植免疫耐受形成提供新的研究思路与方向。</p></sec><sec id="s6"><title>2. 肝移植与免疫耐受</title><p>肝移植是治疗终末期肝病或不能切除的肝脏恶性肿瘤的最佳治疗方法 [<xref ref-type="bibr" rid="hanspub.41657-ref1">1</xref>]，但是术后免疫耐受建立的问题仍然没有得到很好的解决。手术后肝移植耐受被定义为移植物在没有免疫抑制的情况下保持稳定的功能且没有出现临床上显著的不良免疫反应的状态，据报道，肝移植术后自发性耐受的发生率在5.5%到38.1%之间，然而由于缺乏可靠的自发性耐受生物学标志物，目前很难可靠地选择能够成功安全地撤除免疫抑制药物的患者，确认肝移植耐受的唯一有效方法是故意撤除免疫抑制药物，但这可能会引发严重的排斥反应 [<xref ref-type="bibr" rid="hanspub.41657-ref2">2</xref>]。通过多年的研究，多种免疫抑制方案被提出，但是在临床实践当中，这些方案或多或少的具备着疗效不足的缺点或者具有严重的毒副作用。</p><p>W Li等通过小鼠肝移植模型发现肝移植后CD4 + CD25 + Treg扩增，表明其在诱导或维持“自发性”肝移植耐受中起关键作用，随后大量研究证实，Treg在防止移植后排斥反应和诱导免疫耐受中起着核心作用 [<xref ref-type="bibr" rid="hanspub.41657-ref2">2</xref>]。肝移植免疫耐受由多种机制共同作用而建立，肝内固有细胞如肝窦内皮细胞、枯否细胞等，通过分泌大量细胞因子和激活相应抑制通路等来实现 [<xref ref-type="bibr" rid="hanspub.41657-ref4">4</xref>]，而包括上述细胞在内的参与肝移植免疫的细胞作用大多与白介素10有关，这是一种经典的抗炎介质，发现肝脏非实质细胞中的白介素10通路对于抑制排斥反应至关重要 [<xref ref-type="bibr" rid="hanspub.41657-ref5">5</xref>]。而白介素10的产生和作用靶点与Treg紧密联系。此外，肝移植排斥反应在很大程度上是由T细胞介导的，Treg的转移可以用来限制免疫介导的对炎症肝脏的损伤 [<xref ref-type="bibr" rid="hanspub.41657-ref6">6</xref>]。以上研究充分表明了Treg与肝移植免疫耐受之间有着紧密联系，并且Treg在耐受形成当中扮演着重要的角色，利用Treg解决肝移植免疫排斥的问题正成为眼下研究的热点。</p></sec><sec id="s7"><title>3. Treg的功能</title><p>Treg是淋巴细胞，其特征是CD4和CD25分子的表达，更具体地说，是转录因子Foxp3的表达，Foxp3是支持Treg发育和功能的主控基因，是其功能所必须的 [<xref ref-type="bibr" rid="hanspub.41657-ref7">7</xref>]。在免疫自身耐受的各种机制中，内源性Foxp3 + CD25 + CD4 + Treg细胞的免疫抑制是必不可少的，当Treg细胞缺失时自发的自身免疫性疾病的发展就说明了这一点 [<xref ref-type="bibr" rid="hanspub.41657-ref8">8</xref>]。例如，编码Treg特异性转录因子Foxp3的基因突变会损害Treg细胞的发育，并导致致命的多器官自身免疫性疾病，包括免疫失调、多内分泌疾病、肠病和X连锁综合征 [<xref ref-type="bibr" rid="hanspub.41657-ref7">7</xref>]。通过耗尽Foxp3 + CD25 + CD4 + Treg细胞也能够在其他正常啮齿动物中引起类似的自身免疫性疾病 [<xref ref-type="bibr" rid="hanspub.41657-ref8">8</xref>]。</p><p>目前已证实，Treg通过一系列成熟的机制发挥抑制功能，例如，它们分泌抗炎细胞因子，表达共抑制分子(如细胞毒性T淋巴细胞抗原4 (cytotoxic t lymphocyte antigen 4, CTLA4)和淋巴细胞激活基因3蛋白)，并能调节抗原提呈细胞的活性。Treg细胞还可以从微环境中耗尽关键的生长因子，抑制这些因子激活下游通路，使效应细胞“挨饿”进入无能或凋亡状态。此外，Treg细胞具有细胞毒潜能，它们可以通过简单地杀死效应细胞来抑制效应细胞的功能 [<xref ref-type="bibr" rid="hanspub.41657-ref9">9</xref>]。这使得它们能够在不同的环境下控制范围广泛的靶细胞群。此外，Treg还应用于肿瘤、糖尿病治疗等领域，这提示Treg细胞还具有更多的医学价值值得我们去深入研究。</p></sec><sec id="s8"><title>4. Treg诱导肝移植免疫耐受的机制</title><p>Treg诱导肝移植免疫耐受的机制包括 [<xref ref-type="bibr" rid="hanspub.41657-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41657-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.41657-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.41657-ref11">11</xref>]：1) 通过细胞间接触抑制抗原提呈细胞的功能或成熟，通过减少CD80/86共刺激分子的表达，直接影响树突状细胞的抗原提呈，以穿孔素和颗粒酶依赖的方式直接杀伤抗原提呈细胞；2) 通过诱导细胞凋亡来破坏靶细胞；3) 通过腺苷途径引起代谢紊乱，可以刺激色氨酸降解为犬尿氨酸，抑制效应T细胞的功能；4) Treg细胞可被激活，分泌抗炎细胞因子，如白介素-10 (interleukin 10，IL-10)、转化生长因子β、干扰素γ和IL-35来抑制附近的CD8+T细胞功能和免疫应答；5) 竞争性消耗存活的细胞因子，抑制效应细胞的激活，同时组成性表达高亲和力的IL-2受体，它是IL-2的接收器，IL-2是一种强有力的T细胞增殖和T辅助细胞分化的诱导剂，对记忆T细胞的生存和功能是必需的，通过消耗IL-2控制效应细胞的扩张；6) 依赖于Treg细胞上细胞毒性T淋巴细胞相关抗原4的表达，Treg细胞与CD80/CD86高亲和力结合，并通过内吞作用调节其表达，减少效应细胞的激活。</p></sec><sec id="s9"><title>5. 调控Treg抑制功能的重要因子</title><sec id="s9_1"><title>5.1. Foxp3</title><p>胸腺来源的调节性T细胞(tTreg)是中枢免疫耐受的主要介体，而外周来源的调节性T细胞(pTreg)起调节外周免疫耐受的作用，第三种类型的Treg细胞，称为iTreg，只代表体外诱导的Treg细胞 [<xref ref-type="bibr" rid="hanspub.41657-ref12">12</xref>]。这些Treg细胞是如何在不同背景下产生并维持细胞抑制功能的，一直是该领域的一个重要问题。</p><p>虽然几种T细胞类型已被证实具有调节功能，但与生理相关的Treg群体可识别为CD4 + CD25 + T细胞，它们特异性表达名为叉头盒蛋白3的转录因子 [<xref ref-type="bibr" rid="hanspub.41657-ref8">8</xref>]，即Foxp3，这是一种编码转录因子的基因，它调控数百个表面受体和其他核因子的基因，与T细胞增殖、激活和自身免疫相关。Foxp3对CD4 + CD25 + T细胞的免疫抑制功能至关重要，是一种比CD25更可靠的标志物 [<xref ref-type="bibr" rid="hanspub.41657-ref2">2</xref>]。分析表明，细胞内代谢物和代谢途径也调节Foxp3的表达，以及Treg细胞的转录程序和功能可塑性 [<xref ref-type="bibr" rid="hanspub.41657-ref13">13</xref>]。Foxp3表达的缺失对Tregs的稳定性影响巨大，也会导致Treg抑制功能的丧失，并可能破坏免疫平衡，导致排斥反应 [<xref ref-type="bibr" rid="hanspub.41657-ref14">14</xref>]。</p><p>在小鼠和人类中，Foxp3基因的突变会破坏了Treg的发育和功能，并导致严重的自身免疫性疾病，Foxp3是生成功能性Treg所必需的，对于明确Treg细胞的谱系和抑制功能也至关重要 [<xref ref-type="bibr" rid="hanspub.41657-ref13">13</xref>]。Treg在胸腺发育期间，AP1和NFAT (TCR激活下游)结合到Foxp3启动子并驱动表达，Foxo家族蛋白Foxo1和Foxo3也结合启动子区域以及关键的增强子元素，是tTreg生成所必需的。核因子κB(NF-kappa, NFκB)信号对tTreg的产生也很重要，通过诱导Nr4a核受体和CD28共刺激而产生的TCR信号强度都有助于胸腺内Foxp3的上调 [<xref ref-type="bibr" rid="hanspub.41657-ref15">15</xref>]。</p><p>以上说明，Foxp3依赖调控的分子控制是高度复杂的，涉及大量相互作用的辅因子和整合多种上下游通路的能力。</p></sec><sec id="s9_2"><title>5.2. CTLA-4</title><p>CTLA-4是一种与T细胞共刺激分子CD28相关的抑制因子。Treg需要被激活才能变得抑制 [<xref ref-type="bibr" rid="hanspub.41657-ref16">16</xref>]，没有抗原刺激，抗炎细胞因子无法分泌，也无法抑制免疫反应。CD28共刺激对Treg的激活和功能很重要 [<xref ref-type="bibr" rid="hanspub.41657-ref16">16</xref>]，它促进T细胞活化，而CTLA-4具有免疫调节功能，抑制T细胞反应。多种多样的机制被提出来解释CTLA-4的抑制功能，包括CTLA-4结合抗原提呈细胞如树突状细胞上的配体CD80和CD86，通过内吞作用将这些配体从抗原提呈细胞表面移除，从而阻止其有效地激活幼稚的CD4+T细胞 [<xref ref-type="bibr" rid="hanspub.41657-ref17">17</xref>]，以及和CD28竞争与配体的结合，下调配体表达和传递抑制信号 [<xref ref-type="bibr" rid="hanspub.41657-ref18">18</xref>]。</p><p>CTLA-4依赖的大部分免疫调节是通过该分子在Treg室的表达实现的。相反，Treg严重依赖CTLA-4来实现调控功能 [<xref ref-type="bibr" rid="hanspub.41657-ref18">18</xref>]。</p></sec><sec id="s9_3"><title>5.3. IL-2</title><p>在众多细胞因子当中，IL-2显示出其与免疫耐受和免疫激活的高度相关性。Treg的成熟和发育需要持续的IL-2来维持其生存和抑制功能 [<xref ref-type="bibr" rid="hanspub.41657-ref19">19</xref>]。IL-2和其受体可能是控制Treg细胞存活和抑制功能的关键靶点 [<xref ref-type="bibr" rid="hanspub.41657-ref8">8</xref>]。Treg的高亲和力IL-2受体亚基CD25的表达高于效应性T细胞，因此，Treg可以通过竞争性消耗IL-2来抑制效应性细胞的增殖和分化，而当Treg与效应性T细胞接近时，Treg可能通过竞争消耗IL-2来抑制效应性细胞的增殖和分化 [<xref ref-type="bibr" rid="hanspub.41657-ref10">10</xref>]。IL-2信号是Treg细胞最大存活和抑制功能所必需的，它通过信号转导和转录激活因子5b，增强Treg细胞与树突状细胞的相互作用，增强抑制功能 [<xref ref-type="bibr" rid="hanspub.41657-ref11">11</xref>]。</p><p>用IL-2刺激对于维持Treg细胞功能以及在抗原介导的激活后将CD4+T细胞分化为确定的效应T细胞亚群中至关重要，小剂量IL-2的使用可以扩大或激活Treg，也可以扩大T细胞调节因子，并阻止CD4幼稚T细胞分化为滤泡辅助T细胞或促炎辅助T细胞 [<xref ref-type="bibr" rid="hanspub.41657-ref20">20</xref>]。</p><p>此外，S&#233;verine B&#233;zie [<xref ref-type="bibr" rid="hanspub.41657-ref21">21</xref>] 等人发现IL-34参与了CD8 + Treg的体外抑制功能，并证明IL-34在体内和体外的同种异体免疫反应中都有显著的抑制作用，诱导移植耐受，IL-34诱导分化的单核细胞具有选择性扩增的能力，不仅能够维持而且增强了Foxp3 + Treg的抑制能力。</p></sec></sec><sec id="s10"><title>6. 小结</title><p>Treg在肝移植治疗当中已经取得阶段性成果，相关研究已经发现了Treg疗法在肝移植中的可行性和安全性的部分证据，但是由于研究的数量有限和规模较小，Treg在肝移植中的疗效仍有待于明确的证明 [<xref ref-type="bibr" rid="hanspub.41657-ref2">2</xref>]。此外，Treg细胞的抗原特异性、转运行为以及过继转移到人类宿主体内的稳定性仍是过继Treg细胞治疗广泛应用的挑战 [<xref ref-type="bibr" rid="hanspub.41657-ref22">22</xref>]，比如肝内微环境高度富含来自肝树突状细胞的促炎细胞因子IL-1β、IL-6和IL-12，但缺乏关键的Treg细胞生存细胞因子IL-2 [<xref ref-type="bibr" rid="hanspub.41657-ref23">23</xref>]。研究发现T细胞表面嵌合抗原受体(CAR)的转导在肿瘤细胞治疗领域显示出巨大的应用前景，通过基因工程来表达嵌合抗原受体(CARS)，也有可能产生抗原特异性Tregs [<xref ref-type="bibr" rid="hanspub.41657-ref24">24</xref>]。Treg的CAR转导克服了Treg治疗之前固有的几个障碍，为各种情况下抗原特异性免疫抑制治疗提供了希望 [<xref ref-type="bibr" rid="hanspub.41657-ref16">16</xref>]。</p><p>总之，有越来越多的证据表明，在肝移植术后预防免疫排斥反应和肝脏炎症方面，Treg起着至关重要的作用，虽然目前还缺乏有效手段促使该疗法达到完全成熟，但是利用Treg来进行免疫调节的方案已经在临床实践当中发挥了重要作用，对于其更加深入的研究必定可以提高肝移植的成功率。</p></sec><sec id="s11"><title>基金项目</title><p>国家自然科学基金(81670599)。</p></sec><sec id="s12"><title>文章引用</title><p>张 剑,刘 涛,龚建平. 调节性T细胞在肝脏移植免疫耐受中的作用Role of Regulatory T Cells in Immune Tolerance in Liver Transplantation[J]. 临床医学进展, 2021, 11(04): 1630-1635. https://doi.org/10.12677/ACM.2021.114234</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41657-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Trebicka, J., Sundaram, V., Moreau, R., et al. (2020) Liver Transplantation for Acute-on-Chronic Liver Failure: Science or Fiction? Liver Transplantation, 26, 906-915. &lt;br&gt;https://doi.org/10.1002/lt.25788</mixed-citation></ref><ref id="hanspub.41657-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Yu, J., Liu, Z., Li, C., et al. (2020) Regulatory T Cell Therapy Following Liver Transplantation. Liver Transplantation, 27, 264-280. &lt;br&gt;https://doi.org/10.1002/lt.25948</mixed-citation></ref><ref id="hanspub.41657-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.C., Mehdizadeh, S., Smith, J., et al. (2020) Regulatory T Cell Control of Systemic Immunity and Immunotherapy Response in Liver Metastasis. Science Immunology, 5, eaba0759. &lt;br&gt;https://doi.org/10.1126/sciimmunol.aba0759</mixed-citation></ref><ref id="hanspub.41657-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Huang, H., Lu, Y., Zhou, T., et al. (2018) Innate Immune Cells in Immune Tolerance after Liver Transplantation. Frontiers in Immunology, 9, 2401. &lt;br&gt;https://doi.org/10.3389/fimmu.2018.02401</mixed-citation></ref><ref id="hanspub.41657-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, Y., Que, W., Zhu, P., et al. (2020) The Role of Diverse Liver Cells in Liver Transplantation Tolerance. Frontiers in Immunology, 11, 1203. &lt;br&gt;https://doi.org/10.3389/fimmu.2020.01203</mixed-citation></ref><ref id="hanspub.41657-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tedesco, D. and Grakoui, A. (2018) Environmental Peer Pressure: CD4(+) T Cell Help in Tolerance and Transplantation. Liver Transplantation, 24, 89-97. &lt;br&gt;https://doi.org/10.1002/lt.24873</mixed-citation></ref><ref id="hanspub.41657-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ni, X., Tao, J., Barbi, J., et al. (2018) YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity. Cancer Discovery, 8, 1026-1043. &lt;br&gt;https://doi.org/10.1158/2159-8290.CD-17-1124</mixed-citation></ref><ref id="hanspub.41657-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Tanaka, A. and Sakaguchi, S. (2017) Regulatory T Cells in Cancer Immunotherapy. Cell Research, 27, 109-118.  
&lt;br&gt;https://doi.org/10.1038/cr.2016.151</mixed-citation></ref><ref id="hanspub.41657-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Śledzińska, A., Vila de Mucha, M., Bergerhoff, K., et al. (2020) Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4(+) T Cells. Immunity, 52, 151-166.e6.  
&lt;br&gt;https://doi.org/10.1016/j.immuni.2019.12.007</mixed-citation></ref><ref id="hanspub.41657-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Jeffery, H.C., Braitch, M.K., Brown, S., et al. (2016) Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives. Frontiers in Immunology, 7, 334. &lt;br&gt;https://doi.org/10.3389/fimmu.2016.00334</mixed-citation></ref><ref id="hanspub.41657-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Esensten, J.H., Muller, Y.D., Bluestone, J.A., et al. (2018) Regulatory T-Cell Therapy for Autoimmune and Autoinflammatory Diseases: The Next Frontier. The Journal of Allergy and Clinical Immunology, 142, 1710-1718.  
&lt;br&gt;https://doi.org/10.1016/j.jaci.2018.10.015</mixed-citation></ref><ref id="hanspub.41657-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">von Knethen, A., Heinicke, U., Weigert, A., et al. (2020) Histone Deacetylation Inhibitors as Modulators of Regulatory T Cells. International Journal of Molecular Sciences, 21, 2356. &lt;br&gt;https://doi.org/10.3390/ijms21072356</mixed-citation></ref><ref id="hanspub.41657-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Shi, H. and Chi, H. (2019) Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity. Frontiers in Immunology, 10, 2716. &lt;br&gt;https://doi.org/10.3389/fimmu.2019.02716</mixed-citation></ref><ref id="hanspub.41657-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ohkura, N. and Sakaguchi, S. (2020) Transcriptional and Epigenetic Basis of Treg Cell Development and Function: Its Genetic Anomalies or Variations in Autoimmune Diseases. Cell Research, 30, 465-474.  
&lt;br&gt;https://doi.org/10.1038/s41422-020-0324-7</mixed-citation></ref><ref id="hanspub.41657-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Owen, D.L., Mahmud, S.A., Sjaastad, L.E., et al. (2019) Thymic Regulatory T Cells Arise via Two Distinct Developmental Programs. Nature Immunology, 20,195-205. &lt;br&gt;https://doi.org/10.1038/s41590-018-0289-6</mixed-citation></ref><ref id="hanspub.41657-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Boroughs, A.C., Larson, R.C., Choi, B.D., et al. (2019) Chimeric Antigen Receptor Costimulation Domains Modulate Human Regulatory T Cell Function. JCI Insight, 5, e126194. &lt;br&gt;https://doi.org/10.1172/jci.insight.126194</mixed-citation></ref><ref id="hanspub.41657-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Y., Lee, C.K., Lin, C.H., et al. (2019) PD-L1:CD80 Cis-Heterodimer Triggers the Co-Stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity, 51, 1059-1073.e9.  
&lt;br&gt;https://doi.org/10.1016/j.immuni.2019.11.003</mixed-citation></ref><ref id="hanspub.41657-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mitsuiki, N., Schwab, C. and Grimbacher, B. (2019) What Did We Learn from CTLA-4 Insufficiency on the Human Immune System? Immunological Reviews, 287, 33-49. &lt;br&gt;https://doi.org/10.1111/imr.12721</mixed-citation></ref><ref id="hanspub.41657-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Fan, M.Y., Low, J.S., Tanimine, N., et al. (2018) Differential Roles of IL-2 Signaling in Developing versus Mature Tregs. Cell Reports, 25, 1204-1213.e4. &lt;br&gt;https://doi.org/10.1016/j.celrep.2018.10.002</mixed-citation></ref><ref id="hanspub.41657-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Rosenzwajg, M., Lorenzon, R., Cacoub, P., et al. (2019) Immunological and Clinical Effects of Low-Dose Interleukin-2 across 11 Autoimmune Diseases in a Single, Open Clinical Trial. Annals of the Rheumatic Diseases, 78, 209-217.  
&lt;br&gt;https://doi.org/10.1136/annrheumdis-2018-214229</mixed-citation></ref><ref id="hanspub.41657-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Flippe, L., Bezie, S., Anegon, I., et al. (2019) Future Prospects for CD8(+) Regulatory T Cells in Immune Tolerance. Immunological Reviews, 292, 209-224. &lt;br&gt;https://doi.org/10.1111/imr.12812</mixed-citation></ref><ref id="hanspub.41657-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bluestone, J.A. and Tang, Q. (2018) T(reg) Cells—The Next Frontier of Cell Therapy. Science (New York, NY), 362, 154-155. &lt;br&gt;https://doi.org/10.1126/science.aau2688</mixed-citation></ref><ref id="hanspub.41657-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Terry, L.V. and Oo, Y.H. (2020) The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations. Frontiers in Immunology, 11, Article ID: 565518.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2020.565518</mixed-citation></ref><ref id="hanspub.41657-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Fritsche, E., Volk, H.D., Reinke, P., et al. (2020) Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. Trends in Biotechnology, 38, 1099-1112. &lt;br&gt;https://doi.org/10.1016/j.tibtech.2019.12.009</mixed-citation></ref></ref-list></back></article>